Topical hemostat — Competitive Intelligence Brief

Topical hemostat (Topical hemostat) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical hemostat. Area: Surgical.

phase 3 Topical hemostat Surgical Biologic

Target snapshot

Topical hemostat (Topical hemostat) — Ethicon, Inc.. Topical hemostats work by physically obstructing blood flow to a wound site, thereby facilitating clotting and stopping bleeding.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topical hemostat TARGET	Topical hemostat	Ethicon, Inc.	phase 3	Topical hemostat
EVARREST™	EVARREST™	Ethicon, Inc.	marketed	Topical hemostatic agent	Fibrinogen (Factor I) and thrombin (Factor IIa)
Patients receive microporous polysaccharide hemospheres.	Patients receive microporous polysaccharide hemospheres.	Fundación para la Investigación del Hospital Clínico de Valencia	marketed	Topical hemostatic agent
Blood Stopper (Ankaferd)	Blood Stopper (Ankaferd)	Ankara Ataturk Sanatorium Training and Research Hospital	marketed	Topical hemostatic agent
Thrombin JMI	Thrombin JMI	University of Kansas Medical Center	marketed	Topical hemostatic agent	Fibrinogen
Haemostatic solution "Haemoblock" application	Haemostatic solution "Haemoblock" application	Ryazan State Medical University	marketed	Topical hemostatic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical hemostat class)

1. Ethicon, Inc. · 1 drug in this class